USPTO serial 79281159
SAFIRA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 25, 2021
- Examiner
- HARDY LUDLOW, TARAH KIM
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with SAFIRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gregory S. Bernabeo
Gregory S. Bernabeo FisherBroyles LLP1650 Market StreetOne Liberty Place, 36th FloorPhiladelphia, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Artificial anaesthetization apparatus; automatic medical apparatus for dosing animals by injection; automatic medical apparatus for dosing humans by injection; cannulae for anaesthetics with receptacles; disposable hypodermic syringes for medical use; disposable needles for hypodermic syringes; disposable syringes; hypodermic injection apparatus; hypodermic injectors; hypodermic needles; hypodermic needles for injection; hypodermic needles for use in infusion therapy; hypodermic syringes; hypodermic syringes for injections for medical purposes; hypodermic syringes for use in administering injection substances; injectors for medical purposes; infusion apparatus for therapeutic purposes for administering drugs; infusion pumps to deliver medication; injection device for pharmaceuticals; injection instruments without needles; injection needles for medical use; medication fluid injectors; push syringes for medical use; syringes for injections; syringes for medical purposes; anaesthetic apparatus | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Medovate Limited
- Other trademarks owned by Medovate Limited
- Other trademarks owned by Medovate Limited
- Other trademarks owned by Medovate Limited
- Other trademarks in Class 010
- Similar marks named SAFIRA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 25, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 18, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jun 5, 2023 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 5, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 5, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 5, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 4, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 16, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 16, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 25, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 25, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 9, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 9, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 7, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 17, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 17, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 17, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 3, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 3, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 3, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 3, 2021 | ALIE | ASSIGNED TO LIE | — |
| Oct 27, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 15, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 29, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 29, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 14, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 13, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 13, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 24, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 20, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 19, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |